|
Stock-Based Compensation (Narrative) (Details) (USD $)
In Millions, except Share data, unless otherwise specified |
3 Months Ended | 9 Months Ended | 0 Months Ended | 0 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2014
|
Sep. 30, 2013
|
Sep. 30, 2014
|
Sep. 30, 2013
|
Jul. 23, 2014
Common Class C
|
Sep. 30, 2014
Common Class C
|
Jul. 23, 2014
Common Class C
|
Jul. 23, 2014
Common Class A
|
Sep. 30, 2014
Common Class A
|
Jul. 23, 2014
Common Class A
|
Dec. 31, 2013
Common Class A
|
Sep. 30, 2014
SIRIUS XM
|
Sep. 30, 2013
SIRIUS XM
|
Sep. 30, 2014
SIRIUS XM
|
Sep. 30, 2013
SIRIUS XM
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
| Number of shares issued during the period for each share of Series A and Series B stock held by shareholders prior to the distribution | 2 | 2 | |||||||||||||
| Granted | 1,000 | ||||||||||||||
| Weighted average grant-date fair value | $ 38.86 | ||||||||||||||
| Vesting period | 4 years | ||||||||||||||
| Total unrecognized compensation cost related | $ 32 | $ 32 | $ 274 | $ 274 | |||||||||||
| Cost not yet recognized, weighted average period | 1 year 9 months 18 days | 2 years 6 months | |||||||||||||
| Outstanding options | 6,894,000 | 3,450,000 | 3,656,000 | 282,000,000 | 282,000,000 | ||||||||||
| Exercisable options | 4,668,000 | 2,337,000 | 134,000,000 | 134,000,000 | |||||||||||
| Outstanding WAEP | $ 30.72 | $ 30.70 | $ 30.58 | $ 2.67 | $ 2.67 | ||||||||||
| Exercisable WAEP | $ 30.14 | $ 30.11 | $ 2.21 | $ 2.21 | |||||||||||
| Outstanding, aggregate intrinsic value | 112 | 57 | 270 | 270 | |||||||||||
| Exercisable, aggregate intrinsic value | 79 | 40 | 204 | 204 | |||||||||||
| Share-based Compensation | $ 53 | $ 52 | $ 151 | $ 141 | $ 39 | $ 38 | $ 110 | $ 97 | |||||||
| Series C option exercise price as compared to the Series A exercise price (as a percent) | 33.33% | ||||||||||||||
| Option exercise price adjustment (as a percent) | 33.33% | ||||||||||||||